trending Market Intelligence /marketintelligence/en/news-insights/trending/SoRewF3ZjpwP9BUFP84Cow2 content esgSubNav
In This List

UK's NHS to fund patients for Second Sight's 'bionic eye'

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


UK's NHS to fund patients for Second Sight's 'bionic eye'

Second Sight Medical Products Inc. said U.K.'s National Health Service would fund blind patients suffering from retinitis pigmentosa to receive treatment with the company's Argus II retinal prosthesis system, or "bionic eye."

The product would be funded via the commissioning through an evaluation program, which is designed for treatments showing promise while new clinical and patient experience data are collected within a formal evaluation program.

Argus II is reimbursed under a similar program called Forfait Innovation in France.